Imugene Reports 86% Response Rate in Azer-Cel Combination Trial as Cash Outflow Falls
IMU: $0.035 -7.89% · MC: $20M
Imugene reported responses in six of seven evaluable patients in its azer-cel BTKi combination cohort, an 86% response rate, while the CAR T-naïve cohort recorded an 81% response rate after quarter end. Quarterly net operating cash outflow fell 19% from the prior quarter, with staff costs down 51%; cash stood at approximately $5 million before an expected R&D tax incentive refund. The results are early and based on small patient groups, with further follow-up needed to assess response durability.

Comments